The role of post-remission chemotherapy for older patients with acute myelogenous leukemia

References

• Ferrara F, Mirto S, Zagonel V, Pinto A. Acute myeloid leukemia in the elderly: a critical review of therapeutic approaches and appraisal of results of therapy. Leuk Lymp-homa 1998; 29: 375–382
   PubMed Web of Science ®Google Scholar
• Stone R M. The difficult problem of acute myeloid leukemia in the older adult. CA Cancer J Clin 2002; 52: 363–371
   PubMed Web of Science ®Google Scholar
• Estey E H. How I treat older patients with AML. Blood 2000; 96: 1670–1673
   PubMed Web of Science ®Google Scholar
• Sekeres M A, Stone R. Older adults with acute myeloid leukemia. Curr Oncol Rep 2002; 4: 403–409
   PubMedGoogle Scholar
• Lowenberg B, Zittoun R, Kerkhofs H, Jehn U, Abels J, Debusscher L, et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol 1989; 7: 1268–1274
   PubMed Web of Science ®Google Scholar
• Stone R M, Mayer R J. The approach to the elderly patient with acute myeloid leukemia. Hematol Oncol Clin North Am 1993; 7: 65–79
   PubMed Web of Science ®Google Scholar
• Feldman E J. Acute myelogenous leukemia in the older patient. Semin Oncol 1995; 22(Suppl 1)21–24
   PubMed Web of Science ®Google Scholar
• Rees J K, Gray R G, Swirsky D, Hayhoe F G. Principal results of the Medical Research Council's Eighth acute myeloid leukaemia trial. Lancet 1986; 2: 1236–1241
   PubMed Web of Science ®Google Scholar
• Liu Yin J A, Johnson P R, Davies J M, Flanagan N G, Gorst D W, Lewis M J. Mitozantrone and cytosine arabinoside as first-line therapy in elderly patients with acute myeloid leukaemia. Br J Haematol 1991; 79: 415–420
   PubMed Web of Science ®Google Scholar
• Lowenberg B, Suciu S, Archimbaud E, Haak H, Stryckmans P, de Cataldo R, et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy – the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. J Clin Oncol 1998; 16: 872–881
   PubMed Web of Science ®Google Scholar
• Rowe J M, Neuberg D, Friedenberg W, Bennett J M, Paietta E, Makary A Z, et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 2004; 103: 479–485
   PubMed Web of Science ®Google Scholar
• Stone R M, Berg D T, George S L, Dodge R K, Paciucci P A, Schulman P, et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med 1995; 332: 1671–1677
   PubMed Web of Science ®Google Scholar
• Rowe J M, Andersen J W, Mazza J J, Bennett J M, Paietta E, Hayes F A, et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 – 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood 1995; 86: 457–462
   PubMed Web of Science ®Google Scholar
• Lowenberg B, Suciu S, Archimbaud E, Ossenkoppele G, Verhoef G E, Vellenga E, et al. Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group. Blood 1997; 90: 2952–2961
   PubMed Web of Science ®Google Scholar
• Godwin J E, Kopecky K J, Head D R, Willman C L, Leith C P, Hynes H E, et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). Blood 1998; 91: 3607–3615
   PubMed Web of Science ®Google Scholar
• List A F, Kopecky K J, Willman C L, Head D R, Persons D L, Slovak M L, et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 2001; 98: 3212–3220
   PubMed Web of Science ®Google Scholar
• Lancet J E, Willman C L, Bennett J M. Acute myelogenous leukemia and aging. Clinical interactions. Hematol Oncol Clin North Am 2000; 14: 251–267
   PubMed Web of Science ®Google Scholar
• Pinto A, Zagonel V, Ferrara F. Acute myeloid leukemia in the elderly: biology and therapeutic strategies. Crit Rev Oncol Hematol 2001; 39: 275–287
   PubMed Web of Science ®Google Scholar
• Mayer R J, Davis R B, Schiffer C A, Berg D T, Powell B L, Schulman P, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994; 331: 896–903
   PubMed Web of Science ®Google Scholar
• Hamblin T J. Disappointments in treating acute leukemia in the elderly. N Engl J Med 1995; 332: 1712–1713
   PubMed Web of Science ®Google Scholar
• Bennett J M, Catovsky D, Daniel M T, Flandrin G, Galton D A, Gralnick H R, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103: 620–635
   PubMed Web of Science ®Google Scholar
• Kalaycio M. Inpatient management of acute leukemia. Cleve Clin J Med 1997; 64: 385–389
   PubMed Web of Science ®Google Scholar
• Cheson B D, Cassileth P A, Head D R, Schiffer C A, Bennett J M, Bloomfield C D, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990; 8: 813–819
   PubMed Web of Science ®Google Scholar
• Kalaycio M, Pohlman B, Elson P, Lichtin A, Hussein M, Tripp B, et al. Chemotherapy for acute myelogenous leukemia in the elderly with cytarabine, mitoxantrone, and granulocyte-macrophage colony-stimulating factor. Am J Clin Oncol 2001; 24: 58–63
   PubMed Web of Science ®Google Scholar
• Lee S L, Rosner F. Treatment of AGL. Arch Intern Med 1969; 123: 205–206
   PubMed Web of Science ®Google Scholar
• Boggs D R, Wintrobe M M, Cartwright G E. To treat or not to treat acute granulocytic leukemia. II. Arch Intern Med 1969; 123: 568–570
   PubMed Web of Science ®Google Scholar
• Rosner F, Sawitsky A, Grunwald H W, Kanti R R. Letter: acute granulocytic leukemia in the elderly. Arch Intern Med 1976; 136: 120
   PubMed Web of Science ®Google Scholar
• Stone R M, Berg D T, George S L, Dodge R K, Paciucci P A, Schulman P P, et al. Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood 2001; 98: 548–553
   PubMed Web of Science ®Google Scholar
• Feldman E J, Seiter K, Damon L, Linker C, Rugo H, Ries C, et al. A randomized trial of high- versus standard-dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemia. Leukemia 1997; 11: 485–489
   PubMed Web of Science ®Google Scholar
• Ferrara F, Mirto S. Serum LDH value as a predictor of clinical outcome in acute myelogenous leukaemia of the elderly. Br J Haematol 1996; 92: 627–631
   PubMed Web of Science ®Google Scholar
• Nannya Y, Kanda Y, Oshima K, Kaneko M, Yamamoto R, Chizuka A, et al. Prognostic factors in elderly patients with acute myelogenous leukemia: a single center study in Japan. Leuk Lymphoma 2002; 43: 83–87
   PubMed Web of Science ®Google Scholar
• Lowenberg B, Downing J R, Burnett A. Acute myeloid leukemia. N Engl J Med 1999; 341: 1051–1062
   PubMed Web of Science ®Google Scholar
• Walters R S, Kantarjian H M, Keating M J, Estey E H, McCredie K B, Freireich E J. Intensive treatment of acute leukemia in adults 70 years of age and older. Cancer 1987; 60: 149–155
   PubMed Web of Science ®Google Scholar
• Frohling S, Schlenk R F, Stolze I, Bihlmayr J, Benner A, Kreitmeier S, et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol 2004; 22: 624–633
   PubMed Web of Science ®Google Scholar
• Kottaridis P D, Gale R E, Linch D C. Prognostic implications of the presence of FLT3 mutations in patients with acute myeloid leukemia. Leuk Lymphoma 2003; 44: 905–913
   PubMed Web of Science ®Google Scholar
• Gajewski J L, Ho W G, Nimer S D, Hirji K F, Gekelman L, Jacobs A D, et al. Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome. J Clin Oncol 1989; 7: 1637–1645
   PubMed Web of Science ®Google Scholar
• Leith C P, Kopecky K J, Godwin J, McConnell T, Slovak M L, Chen I M, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997; 89: 3323–3329
   PubMed Web of Science ®Google Scholar
• Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison C J, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98: 1312–1320
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kern W, Schoch C, Fonatsch C, Heinecke A, Wormann B, et al. Management of acute myeloid leukemia in elderly patients. J Clin Oncol 1999; 17: 3569–3576
   PubMed Web of Science ®Google Scholar